BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15911314)

  • 1. Napthalimidobenzamide DB-51630: a novel DNA binding agent inducing p300 gene expression and exerting a potent anti-cancer activity.
    Suzuki K; Nagasawa H; Uto Y; Sugimoto Y; Noguchi K; Wakida M; Wierzba K; Terada T; Asao T; Yamada Y; Kitazato K; Hori H
    Bioorg Med Chem; 2005 Jun; 13(12):4014-21. PubMed ID: 15911314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
    Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
    Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptional regulation of the mouse PNRC2 promoter by the nuclear factor Y (NFY) and E2F1.
    Zhou D; Masri S; Ye JJ; Chen S
    Gene; 2005 Nov; 361():89-100. PubMed ID: 16181749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer.
    Lu Z; Luo RZ; Peng H; Huang M; Nishmoto A; Hunt KK; Helin K; Liao WS; Yu Y
    Oncogene; 2006 Jan; 25(2):230-9. PubMed ID: 16158053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1.
    Chen A; Xu J; Johnson AC
    Oncogene; 2006 Jan; 25(2):278-87. PubMed ID: 16170359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo.
    Gao L; Zhang L; Hu J; Li F; Shao Y; Zhao D; Kalvakolanu DV; Kopecko DJ; Zhao X; Xu DQ
    Clin Cancer Res; 2005 Sep; 11(17):6333-41. PubMed ID: 16144938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
    Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
    Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constructing the eukaryotic expression vector to study preliminarily the functions of hammerhead ribozyme targeting base excision repair gene HOGG1.
    Zhang ZZ; Zhang Q; Wu M
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):165-70. PubMed ID: 16608066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6.
    Debes JD; Comuzzi B; Schmidt LJ; Dehm SM; Culig Z; Tindall DJ
    Cancer Res; 2005 Jul; 65(13):5965-73. PubMed ID: 15994976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer activity of litchi fruit pericarp extract against human breast cancer in vitro and in vivo.
    Wang X; Yuan S; Wang J; Lin P; Liu G; Lu Y; Zhang J; Wang W; Wei Y
    Toxicol Appl Pharmacol; 2006 Sep; 215(2):168-78. PubMed ID: 16563451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
    Iljin K; Ketola K; Vainio P; Halonen P; Kohonen P; Fey V; Grafström RC; Perälä M; Kallioniemi O
    Clin Cancer Res; 2009 Oct; 15(19):6070-8. PubMed ID: 19789329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone acetyltransferase p300 promotes the activation of human WT1 promoter and intronic enhancer.
    Shao Y; Lu J; Zhang G; Liu C; Huang B
    Arch Biochem Biophys; 2005 Apr; 436(1):62-8. PubMed ID: 15752709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptional regulation of the homeobox gene NKX3.1 by all-trans retinoic acid in prostate cancer cells.
    Thomas MA; Hodgson MC; Loermans SD; Hooper J; Endersby R; Bentel JM
    J Cell Biochem; 2006 Dec; 99(5):1409-19. PubMed ID: 16817226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
    Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
    Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloning and characterization of lipopolysaccharide-induced tumor necrosis factor alpha factor promoter.
    Shiomi N; Myokai F; Naruishi K; Oyaizu K; Senoo K; Yamaguchi T; Amar S; Takashiba S
    FEMS Immunol Med Microbiol; 2006 Aug; 47(3):360-8. PubMed ID: 16872372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional mapping of the promoter region of the GNB2L1 human gene coding for RACK1 scaffold protein.
    Del Vecchio I; Zuccotti A; Pisano F; Canneva F; Lenzken SC; Rousset F; Corsini E; Govoni S; Racchi M
    Gene; 2009 Feb; 430(1-2):17-29. PubMed ID: 19000751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of an agent selectively targeting DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells.
    Wang H; Han H; Von Hoff DD
    Cancer Res; 2006 Oct; 66(19):9722-30. PubMed ID: 17018631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.